Industry exec asks FDA to help good manufacturers prove to other countries they continue to meet GMPs even if they are not inspected frequently.

The specialty generic manufacturer has a facility dedicated to producing shortage drugs, a seemingly endless commercial opportunity given the development, regulatory and reimbursement challenges in the sterile injectable space.

Agency says it could take enforcement action against pharmacies producing large quantities of the preterm birth drug and physicians should prescribe an approved drug before a compounded version.